Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics, Inc. (GLUE)
:GLUE
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -13.43%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and strategic partnerships, particularly with the success of MRT-6160 and strategic agreement with Novartis. However, challenges such as lower than expected biomarker positivity in certain cancer cohorts and strategic shifts were noted. Overall, the positive developments and financial strength suggest a strong position for future growth.Company Guidance
During the Monte Rosa Therapeutics conference call held on March 20, 2025, several key metrics were discussed regarding the company's clinical and preclinical programs. The Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader, demonstrated significant pharmacodynamic effects with over 90% VAV1 degradation and up to 99% cytokine secretion inhibition, supporting progression to Phase 2 trials. The NEK7 program is on track for an IND submission in the first half of the year, with preclinical data showing potent NEK7 degradation and favorable safety profiles. In oncology, promising early data from the MRT-2359 program in castration-resistant prostate cancer showed a confirmed partial response and two stable diseases among three patients, prompting a focus on this indication. Monte Rosa plans to advance these programs with a strong cash runway extending into 2028.MRT-6160 Phase 1 Study Success
The Phase 1 SAD/MAD study of MRT-6160 in healthy volunteers showed dose-dependent VAV1 degradation exceeding 90%, with significant inhibition of cytokine secretion up to 99%, and was well tolerated.
Strategic Agreement with Novartis
Monte Rosa Therapeutics announced an exclusive strategic development agreement with Novartis for MRT-6160, aiming to accelerate and broaden its development.
NEK7 Program IND Submission On Track
NEK7 program is on track for an IND submission in the first half of the year, with promising preclinical data showing potent degradation of NEK7 and favorable safety profile.
Encouraging Data in Prostate Cancer
Initial data in the castration-resistant prostate cancer cohort showed one confirmed partial response and two stable diseases among three patients.
Strong Financial Position
Monte Rosa Therapeutics has a strong balance sheet with cash runway anticipated into 2028.
---
GLUE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GLUE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $6.70 | $7.06 | +5.37% |
| Nov 07, 2024 | $9.45 | $9.53 | +0.85% |
| Aug 08, 2024 | $3.61 | $3.98 | +10.25% |
| May 09, 2024 | $5.26 | $5.18 | -1.52% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Monte Rosa Therapeutics, Inc. (GLUE) report earnings?
Monte Rosa Therapeutics, Inc. (GLUE) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Monte Rosa Therapeutics, Inc. (GLUE) earnings time?
Monte Rosa Therapeutics, Inc. (GLUE) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GLUE EPS forecast?
GLUE EPS forecast for the fiscal quarter 2025 (Q1) is -0.34.
---